Scarica l'app Stockscreener
14.55
2.68%
-0.40
Precedente Chiudi:
$14.95
Aprire:
$14.95
Volume 24 ore:
35,615
Relative Volume:
0.06
Capitalizzazione di mercato:
$7.95M
Reddito:
-
Utile/perdita netta:
$-9.60M
Rapporto P/E:
-4.6044
EPS:
-3.16
Flusso di cassa netto:
$-8.96M
1 W Prestazione:
-21.56%
1M Prestazione:
+152.05%
6M Prestazione:
+105.51%
1 anno Prestazione:
+67.24%
Intervallo 1D:
$14.40
$15.44
Intervallo di 1 settimana:
$14.40
$20.04
Portata 52W:
$4.9176
$28.60
Artelo Biosciences Inc Stock (ARTL) Company Profile
Nome
Artelo Biosciences Inc
Settore
Industria
Telefono
858-925-7049
Indirizzo
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Confronta ARTL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
14.55 | 13.07M | 0 | -9.60M | -8.96M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-08 | Aggiornamento | D. Boral Capital | Hold → Buy |
| 2021-02-12 | Iniziato | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Borsa (ARTL) Ultime notizie
What analysts say about Artelo Biosciences Inc. stockExplosive portfolio gains - jammulinksnews.com
What drives Artelo Biosciences Inc. stock priceFree Trend-Following Techniques - Autocar Professional
Artelo Biosciences Announces $6.5 Million At-The-Market Offering Agreement - AInvest
Artelo Biosciences Inc. Stock Analysis and ForecastOutstanding stock performance - Autocar Professional
Is Artelo Biosciences Inc. a good long term investmentFree Stock Market Real-Time Monitoring - jammulinksnews.com
Artelo Biosciences' ATM Offering: A Delicate Balance Between Liquidity and Dilution - AInvest
Artelo Biosciences Announces At-The-Market Offering Agreement - TipRanks
What analysts say about Artelo Biosciences Inc. stock outlookMinimized Risk Maximum Return - Newser
Why Artelo Biosciences Inc. stock attracts strong analyst attentionFree Join Group - Newser
How Artelo Biosciences Inc. stock performs during market volatilityFree Smart Money Stock Analysis - Newser
What makes Artelo Biosciences Inc. stock price move sharplySteady Income Ideas - Newser
Artelo Biosciences Plummets Over 22%—What's Driving the Freefall? - AInvest
Artelo Biosciences Stock Soars 114% After Promising Depression Treatment Data - MSN
Artelo Biosciences Shares Climb on Promising Preclinical Osteoarthritis Pain Data - MSN
Artelo Biosciences Plans to Offer 920K Shares of Common Stock - AInvest
Artelo Biosciences completes reverse stock split and reports preliminary Q2 financials - Investing.com Nigeria
D. Boral Capital Upgrades Artelo Biosciences (NASDAQ:ARTL) to Buy - Defense World
D Boral Capital Upgrades Artelo Biosciences (NASDAQ:ARTL) to Strong-Buy - Defense World
Artelo Biosciences presents positive data for arthritis pain drug By Investing.com - Investing.com South Africa
Artelo Biosciences stock soars after positive preclinical pain data By Investing.com - Investing.com Nigeria
Artelo Biosciences stock soars after positive preclinical pain data - Investing.com
Artelo Biosciences Announces Positive Preclinical Efficacy Data for Art26.12 in Osteoarthritis Pain At the 35Th Annual International Cannabinoid Research Society Symposium - MarketScreener
Artelo Biosciences announces preclinical efficacy results of ART26.12 - TipRanks
Artelo Biosciences Soars 30.5% on Promising Depression Drug Data - AInvest
Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium - The Manila Times
Artelo Biosciences presents positive data for arthritis pain drug - Investing.com
Artelo Biosciences Presents Preclinical Data on ART26.12 as Potential Non-Opioid Treatment for Osteoarthritis Pain at ICRS Symposium - Quiver Quantitative
Breakthrough Pain Drug Matches Naproxen Efficacy Without Opioid Side Effects in Latest Trial - Stock Titan
Artelo Biosciences’ ART12.11 Shows Promising Antidepressant Effects in Preclinical Study - Insider Monkey
Artelo Biosciences Soars 12.26% on Positive Drug Data - AInvest
Artelo Biosciences Analyst See It As An Emerging Biotech - Benzinga
Artelo Biosciences upgraded to Buy from Hold at D. Boral Capital - TipRanks
Artelo Biosciences (NASDAQ:ARTL) Stock Price Up 42.5% – Still a Buy? - Defense World
Artelo Biosciences Soars 6.84% on Promising Depression Drug Data - AInvest
Artelo Biosciences Inc Azioni (ARTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):